Amarin Corporation plc Sponsored ADR logo

Amarin Corporation plc Sponsored ADR (AMRN)

Market Closed
16 Oct, 08:00 PM
NASDAQ (CM) NASDAQ (CM)
$
11. 32
-0.25
-2.1608%
$
248.81M Market Cap
- P/E Ratio
- Div Yield
113,700 Volume
- Eps
$ 11.57
Previous Close
Add Transaction
Day Range
11.25 11.63
Year Range
11.25 20.9
Want to track AMRN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript

Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript

Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript

Seekingalpha | 7 months ago
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations

AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations

AMRN jumps 17% after Q4 and FY2025 preliminary sales beat expectations. The release also reflected positive Q4 cash flow and progress on cost cuts.

Zacks | 9 months ago
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down

Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down

AMRN's third-quarter earnings fall short of expectations, but stronger U.S. Vascepa sales push revenues above estimates.

Zacks | 11 months ago
Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript

Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript

Amarin Corporation plc ( AMRN ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Aaron Berg - CEO, President & Director Peter Fishman - Senior VP & CFO Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Mazahir Alimohamed - Leerink Partners LLC, Research Division Presentation Operator Welcome to Amarin Corporation's conference call to discuss its third quarter 2025 financial results. I would like to turn the conference call over to Bob Burrows, Investor Relations for Amarin.

Seekingalpha | 11 months ago
Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains?

Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains?

Amarin (AMRN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 1 year ago
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Zacks | 1 year ago
Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Amarin (AMRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks | 1 year ago
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Here is how Amarin (AMRN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

Zacks | 1 year ago
Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Amarin Corporation plc (NASDAQ:AMRN ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Aaron D. Berg - CEO, President & Director Mark Marmur - Corporate Participant Peter L.

Seekingalpha | 1 year ago
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect

Amarin Gears Up to Report Q2 Earnings: Here's What to Expect

AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.

Zacks | 1 year ago
3 Strong Buy Breakout Stocks for Explosive Returns

3 Strong Buy Breakout Stocks for Explosive Returns

MAMA, BSET and AMRN meet breakout criteria with strong earnings growth and prices near 52-week highs.

Zacks | 1 year ago
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus

Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus

Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.

Zacks | 1 year ago
Loading...
Load More